Airway relaxation induced by NOC-5 and its modulation by related compounds
| Experimental conditions | Relaxation (% of maximal contraction) | ||
| Peak | Sustained | n | |
| 5-HT–contracted airways | |||
| NOC-5 (10 µM) | 44 ± 6 | 12 ± 3 | 7 |
| SNAP (50 µM) | 49 ± 12 | 17 ± 9 | 3 |
| NOC-5 + ZAP (10 µM) | 49 ± 8 | 46 ± 6b | 7 |
| NOC-5 + ODQ (5 µM) | 4 ± 2a | 2 ± 1b | 6 |
| NOC-5 + Rp-8-pCPT-cGMPS (20 µM) | 5 ± 3a | 3 ± 2b | 5 |
| ACH-contracted airways | |||
| NOC-5 (10 µM) | 40 ± 7 | 11 ± 6 | 3 |
| NOC-5 + ZAP (10 µM) | 46.4 ± 8.7 | 45.7 ± 7.9b | 3 |
| NOC-5 + VAR (1 µM) | 53.1 ± 9.8 | 52.3 ± 9.2b | 5 |
| Experimental conditions | Relaxation (% of maximal contraction) | ||
| Peak | Sustained | n | |
| 5-HT–contracted airways | |||
| NOC-5 (10 µM) | 44 ± 6 | 12 ± 3 | 7 |
| SNAP (50 µM) | 49 ± 12 | 17 ± 9 | 3 |
| NOC-5 + ZAP (10 µM) | 49 ± 8 | 46 ± 6b | 7 |
| NOC-5 + ODQ (5 µM) | 4 ± 2a | 2 ± 1b | 6 |
| NOC-5 + Rp-8-pCPT-cGMPS (20 µM) | 5 ± 3a | 3 ± 2b | 5 |
| ACH-contracted airways | |||
| NOC-5 (10 µM) | 40 ± 7 | 11 ± 6 | 3 |
| NOC-5 + ZAP (10 µM) | 46.4 ± 8.7 | 45.7 ± 7.9b | 3 |
| NOC-5 + VAR (1 µM) | 53.1 ± 9.8 | 52.3 ± 9.2b | 5 |
PDE-5 inhibitors: ZAP and vardenifil (VAR); sGC inhibitor (ODQ); PKG inhibitor (Rp-8-pCPT-cGMPS). The peak and sustained relaxation of airways in response to NOC-5 in the absence or presence of ZAP, ODQ, and Rp-8-pCPT-cGMPS calculated from experiments similar to those shown in Figs. 2 and 3.
P < 0.05 compared to peak relaxation induced by NOC-5 alone.
P < 0.05 compared to sustained relaxation induced by NOC-5 alone.